Shah M V, Hook C C, Call T G, Go R S
Division of Hematology, Mayo clinic, Rochester, MN, USA.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
Blood Cancer J. 2016 Aug 5;6(8):e455. doi: 10.1038/bcj.2016.59.
Large granular lymphocyte (LGL) leukemia is a lymphoproliferative disorder of cytotoxic cells. T-cell LGL (T-LGL) leukemia is characterized by accumulation of cytotoxic T cells in blood and infiltration of the bone marrow, liver or spleen. Population-based studies have not been reported in LGL leukemia. We present clinical characteristics, natural history and risk factors for poor survival in patients with LGL leukemia using the Surveillance, Epidemiology, and End Results Program (SEER) and the United States National Cancer Data Base (NCDB). LGL leukemia is an extremely rare disease with the incidence of 0.2 cases per 1 000 000 individuals. The median age at diagnosis was 66.5 years with females likely to be diagnosed at 3 years earlier compared with males. Analysis of patient-level data using NCDB (n=978) showed that 45% patients with T-LGL leukemia required some form of systemic treatment at the time of diagnosis. T-LGL leukemia patients have reduced survival compared with general population, with a median overall survival of 9 years. Multivariate analysis showed that age >60 years at the time of diagnosis and the presence of significant comorbidities were independent predictors of poor survival.
大颗粒淋巴细胞(LGL)白血病是一种细胞毒性细胞的淋巴增殖性疾病。T细胞LGL(T-LGL)白血病的特征是血液中细胞毒性T细胞积聚以及骨髓、肝脏或脾脏浸润。尚未有基于人群的LGL白血病研究报道。我们利用监测、流行病学和最终结果计划(SEER)以及美国国家癌症数据库(NCDB),呈现LGL白血病患者的临床特征、自然病史和生存不良的危险因素。LGL白血病是一种极为罕见的疾病,发病率为每100万人中有0.2例。诊断时的中位年龄为66.5岁,女性比男性可能早3年被诊断。使用NCDB(n = 978)对患者层面数据进行分析显示,45%的T-LGL白血病患者在诊断时需要某种形式的全身治疗。T-LGL白血病患者的生存率低于普通人群,中位总生存期为9年。多变量分析显示,诊断时年龄>60岁以及存在显著合并症是生存不良的独立预测因素。